Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Recommendations

Info

238 Applying Pharmacogenomics in Therapeutics63. Hizawa N. Pharmacogenetics of beta2-agonists. Allergology International 2011;60:239–46.64. Konno S, Makita H, Hasegawa M, et al. Beta2-adrenergic receptor polymorphismsas a determinant of preferential bronchodilator responses to beta2-agonist and anticholinergicagents in Japanese patients with chronic obstructive pulmonary disease.Pharmacogenetics and Genomics 2011;21:687–93.65. Hizawa N, Makita H, Nasuhara Y, et al. Beta2-adrenergic receptor genetic polymorphismsand short-term bronchodilator responses in patients with COPD. Chest2007;132:1485–92.66. Mokry M, Joppa P, Slaba E, et al. Beta2-adrenergic receptor haplotype and bronchodilatorresponse to salbutamol in patients with acute exacerbations of COPD. MedicalScience Monitor 2008;14:CR392–8.67. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta 2-agonists in development forasthma and chronic obstructive pulmonary disease. Expert Opinion on InvestigationalDrugs 2005;14:775–83.68. Yelensky R, Li Y, Lewitzky S, et al. A pharmacogenetic study of ADRB2 polymorphismsand indacaterol response in COPD patients. The Pharmacogenomics Journal2012;12:484–8.69. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches.Nature Medicine 2012;18:716–25.70. Fanta CH. Asthma. The New England Journal of Medicine 2009;360:1002–14.71. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation definesmajor subphenotypes of asthma. American Journal of Respiratory and Critical CareMedicine 2009;180:388–95.72. Izuhara K, Arima K, Yasunaga S. IL-4 and IL-13: Their pathological roles in allergicdiseases and their potential in developing new therapies. Current Drug Targets 2002;1:263–9.73. Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generationand mast cell effector function in mice deficient in IL-4 and IL-13. The Journal ofImmunology 2005;174:7716–24.74. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4in experimental asthma. Science 1998;282:2261–3.75. Chatila TA. Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trendsin Molecular Medicine 2004;10:493–9.76. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health careuse, and mortality in the United States, 2001–2010. NCHS data brief, no. 94. NationalCenter for Health Statistics, Hyattsville, ML; 2012.77. Janssens T, Ritz T. Perceived triggers of asthma: Key to symptom perception and management.Clinical and Experimental Allergy 2013;43:1000–8.78. Ritz T, Steptoe A, Bobb C, Harris AH, Edwards M. The asthma trigger inventory:Validation of a questionnaire for perceived triggers of asthma. Psychosomatic Medicine2006;68:956–65.79. Ritz T, Kullowatz A, Bobb C, et al. Psychological triggers and hyperventilation symptomsin asthma. Annals of Allergy, Asthma and Immunology 2008;100:426–32.80. Ege MJ, Mayer M, Normand AC, et al. Exposure to environmental microorganisms andchildhood asthma. The New England Journal of Medicine 2011;364:701–9.81. Karvonen AM, Hyvarinen A, Gehring U, et al. Exposure to microbial agents inhouse dust and wheezing, atopic dermatitis and atopic sensitization in early childhood:A birth cohort study in rural areas. Clinical and Experimental Allergy 2012;42:1246–56.82. Koh YY, Kim CK. The development of asthma in patients with allergic rhinitis. CurrentOpinion in Allergy and Clinical Immunology 2003;3:159–64.
Applying Pharmacogenomics in the Therapeutics of Pulmonary Diseases23983. Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-derived TSLP triggers progressionfrom epidermal-barrier defects to asthma. PLoS Biology 2009;7:e1000067.84. Wechsler ME, Kelley JM, Boyd IO, et al. Active albuterol or placebo, sham acupuncture,or no intervention in asthma. The New England Journal of Medicine 2011;365:119–26.85. Jat KR, Khairwa A. Levalbuterol versus albuterol for acute asthma: A systematicreview and meta-analysis. Pulmonary Pharmacology & Therapeutics 2013;26:239–48.86. Beumer HM. Pirbuterol versus orciprenaline aerosols in the treatment of bronchialasthma. International Journal of Clinical Pharmacology, Therapy, and Toxicology1983;21:147–66.87. Cates CJ, Oleszczuk M, Stovold E, Wieland LS. Safety of regular formoterol orsalmeterol in children with asthma: An overview of Cochrane reviews. The CochraneDatabase of Systematic Reviews 2012;10:CD010005.88. Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clinicaland Experimental Allergy 2010;40:1732–41.89. Dimov VV, Casale TB. Immunomodulators for asthma. Allergy, Asthma & ImmunologyResearch 2010;2:228–34.90. Misawa M, Takenouchi K, Shirakawa Y, Yanaura S. Effects of mast cell stabilizers ona new bronchial asthma model using compound 48/80 in dogs. Japanese Journal ofPharmacology 1987;44:197–205.91. Melani AS. Flunisolide for the treatment of asthma. Expert Review of ClinicalPharmacology 2014;7:251–8.92. Berger WE, Bensch GW, Weinstein SF, et al. Bronchodilation with mometasonefuroate/formoterol fumarate administered by metered-dose inhaler with and withouta spacer in children with persistent asthma. Pediatric Pulmonology 201;49:441–50.93. Price D, Hillyer EV. Fluticasone propionate/formoterol fumarate in fixed-dosecombination for the treatment of asthma. Expert Review of Respiratory Medicine2014;8:275–91.94. Profita M, Riccobono L, Bonanno A, et al. Effect of nebulized beclomethasone onairway inflammation and clinical status of children with allergic asthma and rhinitis:A randomized, double-blind, placebo-controlled study. International Archives ofAllergy and Immunology 2013;161:53–64.95. Pilcher J, Patel M, Smith A, et al. Combination budesonide/formoterol inhaler as maintenanceand reliever therapy in Maori with asthma. Respirology 2014;19:842–51.96. Mometasone/formoterol (dulera) for asthma. The Medical Letter on Drugs andTherapeutics 2010;52:83–4.97. Ober C, Yao TC. The genetics of asthma and allergic disease: A 21st century perspective.Immunological Reviews 2011;242:10–30.98. Grotenboer NS, Ketelaar ME, Koppelman GH, Nawijn MC. Decoding asthma:Translating genetic variation in IL33 and IL1RL1 into disease pathophysiology. TheJournal of Allergy and Clinical Immunology 2013;131:856–65.99. Watson B, Gauvreau GM. Thymic stromal lymphopoietin: A central regulator of allergicasthma. Expert Opinion on Therapeutic Targets 2014;18:771–85.100. Birben E, Sahiner UM, Karaaslan C, et al. The genetic variants of thymic stromal lymphopoietinprotein in children with asthma and allergic rhinitis. International Archivesof Allergy and Immunology 2014;163:185–92.101. Savenije OE, Mahachie John JM, Granell R, et al. Association of IL33-IL-1 receptorlike1 (IL1RL1) pathway polymorphisms with wheezing phenotypes and asthma inchildhood. The Journal of Allergy and Clinical Immunology 2014;134:170–7.102. Wu H, Romieu I, Sienra-Monge JJ, Li H, del Rio-Navarro BE, London SJ. Geneticvariation in ORM1-like 3 (ORMDL3) and gasdermin-like (GSDML) and childhoodasthma. Allergy 2009;64:629–35.
Page 1:
ApplyingPharmacogenomicsin Therapeu
Page 5 and 6:
ApplyingPharmacogenomicsin Therapeu
Page 7:
DedicationWe dedicate this book to
Page 10 and 11:
viiiContentsChapter 10 Pharmacogeno
Page 13 and 14:
EditorsXiaodong Feng, PhD, PharmD,
Page 15 and 16:
ContributorsWeiguo Chen, PhDDepartm
Page 17 and 18:
1Concepts inPharmacogenomics andPer
Page 19 and 20:
Concepts in Pharmacogenomics and Pe
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
2Principles ofPharmacogeneticBiotec
Page 51 and 52:
Principles of Pharmacogenetic Biote
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65:
Page 68 and 69:
52 Applying Pharmacogenomics in The
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
4 ApplyingPharmacogenomicsin Drug D
Page 93 and 94:
Applying Pharmacogenomics in Drug D
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
5 Pharmacogenomicsand Laboratory Me
Page 113 and 114:
Pharmacogenomics and Laboratory Med
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157:
Page 160 and 161:
144 Applying Pharmacogenomics in Th
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205: 188 Applying Pharmacogenomics in Th
Page 217 and 218: 8Clinical Applicationsof Pharmacoge
Page 219 and 220: Pharmacogenomics of CNS Disorder Tr
Page 237 and 238: 9 ApplyingPharmacogenomicsin the Th
Page 239 and 240: Applying Pharmacogenomics in the Th
Page 253: Applying Pharmacogenomics in the Th
Page 259 and 260: 10Pharmacogenomics andAlternative M
Page 261 and 262: Pharmacogenomics and Alternative Me
Page 287 and 288: 11 PharmacoeconogenomicsA Good Marr
Page 289 and 290: Pharmacoeconomics of Pharmacogenomi
Page 303 and 304: 5’3’5’3’ 5’3’ 5’3’3
Page 305 and 306:
1 2 3 4 5Vysis LSI BCR/ABL + 9q34 t
Page 307:
BIOMEDICAL SCIENCEApplying Pharmaco
show all

Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Create successful ePaper yourself

Delete template?

Save as template?